uniQure (NASDAQ:QURE) Director Robert Gut Sells 7,552 Shares

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 7,552 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $26.05, for a total value of $196,729.60. Following the sale, the director owned 27,435 shares in the company, valued at approximately $714,681.75. The trade was a 21.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Thursday, June 11th, Robert Gut sold 2,726 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $73,765.56.

uniQure Stock Performance

uniQure stock traded up $0.75 during trading hours on Friday, hitting $27.57. 835,627 shares of the stock traded hands, compared to its average volume of 2,601,234. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm’s 50 day moving average price is $22.31 and its 200-day moving average price is $21.76. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, equities analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on QURE. HC Wainwright lowered their target price on uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Barclays lowered their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Institutional Trading of uniQure

A number of hedge funds have recently modified their holdings of QURE. Jones Financial Companies Lllp raised its holdings in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. CIBC Private Wealth Group LLC acquired a new position in uniQure in the 3rd quarter worth about $50,000. Torren Management LLC acquired a new position in uniQure in the 4th quarter worth about $28,000. FNY Investment Advisers LLC raised its holdings in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. Finally, IFP Advisors Inc acquired a new position in uniQure in the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.